Novavax Inc. (NVAX) shares plummeted on Wednesday after the FDA placed a clinical hold on the company’s Investigational New Drug (IND) application for its combined COVID-19/influenza vaccine candidate. The hold was triggered by a single instance of motor neuropathy reported in a participant outside the U.S., raising concerns about the vaccine’s safety.
Novavax Inc. (NVAX) has received European marketing authorization for its updated Nuvaxovid COVID-19 vaccine, targeting the JN.1 variant and providing protection against several other variants. This approval marks a significant milestone for the company, although the vaccine hasn’t yet received full FDA approval in the US.
The FDA has granted Emergency Use Authorization to Novavax’s COVID-19 vaccine for individuals aged 12 and older. This protein-based vaccine targets the dominant circulating COVID-19 variant and offers protection against numerous subvariants. It is expected to be available within a week.
